Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

EQS-News: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
EQS-News: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
EQS-News: Evotec announces progress in strategic protein degradation partnership with Bristol Myers Squibb
eqs_en 
0 16.03.23
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
eqs_en 
0 15.03.23
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
eqs_en 
0 15.03.23
EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
eqs_en 
0 14.03.23
EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer
eqs_en 
0 14.03.23
EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
eqs_en 
0 09.03.23
EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
EQS-News: Invitation to MorphoSys’ Full Year Results 2022 Conference Call on March 16, 2023
eqs_en 
0 09.03.23
EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
eqs_en 
0 02.03.23
EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
EQS-News: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs
eqs_en 
0 02.03.23
EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
eqs_en 
0 02.03.23
EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
EQS-Adhoc: Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
eqs_en 
0 02.03.23
EQS-News: Evotec receives € 150 m loan from European Investment Bank
EQS-News: Evotec receives € 150 m loan from European Investment Bank
EQS-News: Evotec receives € 150 m loan from European Investment Bank
eqs_en 
0 10.02.23
EQS-News: Evotec and Related Sciences expand integrated drug discovery and development partnership
EQS-News: Evotec and Related Sciences expand integrated drug discovery and development partnership
EQS-News: Evotec and Related Sciences expand integrated drug discovery and development partnership
eqs_en 
0 09.02.23
EQS-Adhoc: Bayer Aktiengesellschaft: William N. Anderson to succeed Werner Baumann as Chairman of the Board of Management of Bayer AG
EQS-Adhoc: Bayer Aktiengesellschaft: William N. Anderson to succeed Werner Baumann as Chairman of the Board of Management of Bayer AG
EQS-Adhoc: Bayer Aktiengesellschaft: William N. Anderson to succeed Werner Baumann as Chairman of the Board of Management of Bayer AG
eqs_en 
0 08.02.23
EQS-Adhoc: Bayer Aktiengesellschaft: William N. Anderson to succeed Werner Baumann as Chairman of the Board of Management of Bayer AG
EQS-Adhoc: Bayer Aktiengesellschaft: William N. Anderson to succeed Werner Baumann as Chairman of the Board of Management of Bayer AG
EQS-Adhoc: Bayer Aktiengesellschaft: William N. Anderson to succeed Werner Baumann as Chairman of the Board of Management of Bayer AG
eqs_en 
0 08.02.23
EQS-News: Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer
EQS-News: Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer
EQS-News: Evotec SE: Laetitia Rouxel to succeed Enno Spillner as Chief Financial Officer
eqs_en 
0 07.02.23
EQS-News: Evotec announces agreement with Janssen to develop immune-based therapies
EQS-News: Evotec announces agreement with Janssen to develop immune-based therapies
EQS-News: Evotec announces agreement with Janssen to develop immune-based therapies
eqs_en 
0 26.01.23
EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
eqs_en 
0 09.01.23
EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
EQS-News: MorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
eqs_en 
0 09.01.23
EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
eqs_en 
0 05.01.23
EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
EQS-News: MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
eqs_en 
0 05.01.23
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
eqs_en 
0 05.01.23
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
EQS-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
eqs_en 
0 05.01.23
EQS-News: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
EQS-News: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
EQS-News: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
eqs_en 
0 20.12.22
EQS-News: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
EQS-News: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
EQS-News: Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
eqs_en 
0 20.12.22